Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200
Active Not Recruiting
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/01/2025
Locations: GSK Investigational Site, Atlanta, Georgia +39 locations
Conditions: Multiple Myeloma
Register for Updates
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
NCT04681105
Active Not Recruiting
This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Register for Updates
Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery
NCT04156581
Completed
Enhanced recovery pathways (ERPs) emphasize evidence-based, multimodal anesthetic and analgesic choices to minimize opioid consumption while providing adequate pain control after surgery. Although ERPs for spine surgery are now being described, few pathways include regional analgesia. The Erector Spinae Plane Block (ESPB) may represent a novel opportunity to incorporate regional analgesia into ERPs for spine surgery. To date, there is minimal data to support the utility of ESPB in spine surgery,... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/23/2024
Locations: Hospital for Special Surgery, New York, New York
Conditions: Opioid Use, Pain, Postoperative
Register for Updates
Erector Spinae Plane Blocks for Adolescent Idiopathic Scoliosis
NCT04500613
Completed
Pediatric spinal fusion (PSF) surgery is a painful procedure that can treat adolescent idiopathic scoliosis (AIS). One technique that can potentially reduce patients' pain levels and need for opioid medication is the ultrasound-guided Erector Spinae Plane Block (ESPB). The ESP block is a technique that involves injecting an anesthetic medication into the muscles of the lower back on both sides of the spine. Previous studies have shown that ESPB application led to a reduction in opioid use, and t... Read More
Gender:
ALL
Ages:
Between 10 years and 19 years
Trial Updated:
12/23/2024
Locations: Hospital for Special Surgery (HSS), New York, New York
Conditions: Pain, Postoperative, Opioid Use, Recruitment
Register for Updates
Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery
NCT05720949
Completed
The purpose of this randomized controlled trial is to assess a new analgesia regimen that includes the addition of genicular never blocks to our current standard regimen of peripheral nerve blocks, which includes an adductor canal block (ACB) and interspace between the popliteal artery and capsule of the posterior knee block (IPACK). The main questions it aims to answer are: 1. Does addition of genicular nerve blocks to standard peripheral block regimen significantly reduce the mean opioid cons... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/23/2024
Locations: HSS Sports Medicine Institute West Side, New York, New York
Conditions: ACL, Anterior Cruciate Ligament Injuries
Register for Updates
Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)
NCT03094663
Completed
A comparison of two pain control methods - the combination of Adductor Canal Block (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI) - in patients undergoing total knee arthroplasty. Primary outcome is NRS pain scores with ambulation on postoperative day one (24 hours post-block administration).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/23/2024
Locations: Hospital For Special Surgery, New York, New York
Conditions: Knee Arthropathy
Register for Updates
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT03215030
Completed
The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Highlands Oncology Group, Springdale, Arkansas +93 locations
Conditions: Multiple Myeloma
Register for Updates
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
NCT03367572
Completed
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Hawaii MU NCORP, Honolulu, Hawaii +17 locations
Conditions: Breast Carcinoma
Register for Updates
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662
Active Not Recruiting
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. In this stu... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Multiple Myeloma
Register for Updates
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321
Recruiting
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
12/17/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Register for Updates
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
NCT03030261
Active Not Recruiting
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durab... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/16/2024
Locations: Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado +2 locations
Conditions: Multiple Myeloma in Relapse
Register for Updates
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764
Active Not Recruiting
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates